What is UroGen Pharma's price / book?

UroGen Pharma (URGN) reported price / book of 20.5× in Q3 2024.

What does price / book mean?

Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

UroGen Pharma URGN Price / book

Price / book at other companies

Bristol-Myers SquibbBMY

6.2×-1.0×

PfizerPFE

1.8×+0.2×

Johnson & JohnsonJNJ

7.3×+2.1×

Merck & Co.MRK

6.5×+1.8×

Tyra Biosciences, Inc.TYRA

5.3×+3.8×

CG OncologyCGON

5.2×+2.6×

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.73B+71.7%

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Calculated from UroGen Pharma’s reported figures.

market cap/total stockholders equity=20.5×

Based on the most recent quarter.

The official record: UroGen Pharma’s 10-Q, filed November 6, 2024, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's price / book?: UroGen Pharma (URGN) reported price / book of 20.5× in Q3 2024.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.